Spiroxatrine

Research use only, not for human use.

Spiroxatrine (R 5188) is a selective and potent 5-HT1α and α2-adrenergic dual antagonist with sedative activity, and inhibitory effects on 5-HT1α, 5-HT1β, 5-HT2, and dopamine receptors.

Spiroxatrine (R 5188) is a selective, dual antagonist of 5-HT1α and α2-adrenergic, with the Ki values of 3.94, 224000, 118.5 nM for 5-HT1α, 5-HT1β and 5-HT2, respectively. Spiroxatrine (R 5188) has a sedative effect.

——

Animal Model:The nerve injury rat model and Carrageenan (HY-125474)-induced rat inflammation model Dosage:1, 10, 25 ug, 5 days Administration:Intraperitoneal injection (i.p.)Result:Increased hindpaw withdrawal latencies to thermal and mechanical stimulation.Animal Model:Fluoxetine (HY-B0102) -induced reduction of ethanol Intake by the P Line of rats Dosage:4 mg/kg/day, 5 mins Administration:Intraperitoneal injection (i.p.)Result:Increased the voluntary oral ethanol intake induced by Fluoxetine (HY-B0102) in the selectively bred alcohol-preferring P line of rats.

——

GPCR/G Protein

5-HT Receptor

5-HT Receptor | Dopamine Receptor | Adrenergic Receptor

——

——

1054-88-2

379.45

C22H25N3O3

>98% (HPLC)

In Vitro:?DMSO : 1.92 mg/mL (5.06 mM; Ultrasonic (<60°C)

O=C1C2(N(CN1)C3=CC=CC=C3)CCN(CC4OC=5C(OC4)=CC=CC5)CC2

——

(-20℃)

With Ice Pack

≥ 2 years